Diabetic kidney disease
- ACEi/ARB if HTN + albuminuria
- SGLT2 inhibitor is disease-modifying therapy
- GLP-1–based therapy adds metabolic/CV benefit
- Finerenone if persistent albuminuria + K permits
- Tight BP and individualized glucose control
- Monitor eGFR, urine albumin + potassium
- Avoid dual ACEi + ARB blockade
Use at a glance
- ACEi/ARB if HTN + albuminuria
Treatment options
- SGLT2 inhibitor is disease-modifying therapy
- GLP-1–based therapy adds metabolic/CV benefit
- Tight BP and individualized glucose control
Choosing treatment
- Finerenone if persistent albuminuria + K permits
Monitoring / follow-up
- Monitor eGFR, urine albumin + potassium
- Avoid dual ACEi + ARB blockade
Self-check
- What should generally be avoided in Diabetic kidney disease?
dual ACEi + ARB blockade.
- What should be monitored during treatment of Diabetic kidney disease?
eGFR, urine albumin + potassium.
Drugs used for this (1)
All clinical uses · Open the interactive console ↗
